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Abstract 
Background: The national antiretroviral therapy in the Republic of Chad provides free of charge antiretroviral regi‑
mens and therapeutic monitoring for patients receiving antiretroviral therapy nationwide. For a successful program‑
matic uptake, these efforts merit to be supported by thorough assessments of antiretroviral therapy response and 
HIV‑1 drug resistance surveillance, especially with risks of cross‑resistance due to the gradual stavudine phasing out in 
such national settings. We therefore evaluated the virological response to antiretroviral therapy, HIV‑1 drug resistance 
emergence and circulating HIV‑1 clades in a Chad context. A cross‑sectional and prospective study was conducted 
among 116 patients (41 [δ ± 6.87] years, 59% female) receiving first‑line antiretroviral therapy for ≥ 6 months in Ndja‑
mena, Chad, in 2011–2012, enrolled consecutively. To ensure accuracy, plasma viral load was concomitantly measured 
using Abbott Real‑Time and Cobas AmpliPrep/TaqMan (v2.0), and virological failure defined as ≥ 1000 HIV‑1 RNA cop‑
ies/ml. Plasma from patients experiencing virological failure were processed for sequencing of HIV‑1 protease‑reverse 
transcriptase using the ANRS‑AC.11 resistance testing protocol; drug resistant mutations were interpreted using the 
ANRS‑AC11 algorithm; and phylogenetic analysis was performed using MEGA.v.6.
Results: Majority of patients was receiving zidovudine plus lamivudine plus nevirapine (46%), stavudine plus lamivu‑
dine plus nevirapine (41%) and tenofovir plus emtricitabine plus efavirenz (11%), for a median time‑on‑treatment of 
5 [IQR 4–7] years. The rate of virological failure was 43% (50/116), with 86% (43/50) sequencing performance. Overall, 
32% (37/116) patients presented ≥ one major drug resistant mutation(s), with 29% (34/116) to nucleos(t)ide reverse 
transcriptase inhibitors (67% [29/43] M184V/I, 30% [13/43] T215Y/F, 19% [8/43] V75A/F/I/L/M, 9% [4/43] K70P/R/W, 9% 
[4/43] K219E/N/Q and 5% [2/43] A62V); 86% (37/43) to non‑nulceos(t)ide reverse transcriptase inhibitors (30% [13/43] 
K103N/S/E, 26% [11/43] Y181C/V/F/L, 2% [1/43] L100I, 2% [1/43] F227L, 2% [1/43] P225H); and 2% (1/43) to protease 
inhibitors (M46I, I54V, V82S). Six HIV‑1 subtypes were found: 30% circulating recombinant form (CRF02_AG), 30% J, 
16% G, 9% A, 9% D, 5% F.
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Background
HIV/AIDS remains a major cause of death worldwide, 
and especially in sub-Saharan Africa (SSA) where over 
71% of the global AIDS epidemic is concentrated in only 
12% of the world population. In spite of a reduction in 
HIV-associated morbidity and mortality in SSA, about 
half of people living with HIV (PLHIV) still ignore their 
status, suggesting a potential growing burden of HIV in 
this region of the world [1–3].
Located in central Africa, Chad is a country with 3.3% 
of HIV prevalence in the sexually active population (i.e. 
15–45  years) for a national population of 11.4 million 
inhabitants [4–6]. Interestingly, Chad is the fifth larg-
est African country, partly bordered by Cameroon, a 
country known as the epicenter of HIV with a broad 
genetic diversity that includes several HIV-1 groups M, 
N, O and P, and HIV-2, as well as several subtypes and 
recombinants [7–11]. HIV-1 group-M predominates the 
molecular epidemiology in Chad (subtypes A, D, F, G, 
CRF01_AE, CRF02_AG and CRF11_cpx); few cases of 
group O have been reported while groups N and P, while 
HIV-2 have never been identified [10, 12, 13]. Explor-
ing the extent of HIV diversity in Chad would therefore 
provide updates and related impact on the dynamics of 
national AIDS epidemics for relevant policy-making [14].
ART management and laboratory monitoring are effec-
tive and free-of-charge in the national AIDS program in 
Chad since 2007, with first-line regimens consisting of 
two nucleoside reverse transcriptase inhibitor (NRTI) 
and one non-NRTI (NNRTI). As per the World Health 
Organization (WHO) recommended guidelines, preferred 
first-line regimens since 2012 consist of “tenofovir (TDF), 
emtricitabine (FTC) and efavirenz (EFV)” or “zidovudine 
(AZT), lamivudine (3TC) and nevirapine (NVP)”; follow-
ing phasing-out of Triomune due to lipodistrophy/lipoat-
rophy and peripheral neuropathy significantly associated 
with “stavudine” (d4T)-containing regimens [5, 8, 14]. 
However, at the moment of the study, viral load testing 
was implemented only at the national reference hospital 
laboratory. Viral load was mainly performed as needed, 
after treatment failure based on immunological and/or 
clinical parameters, thus indicating a limited accessibil-
ity to virological monitoring nationwide during the study 
period. Thus, mastering HIVDR profile in such context 
will help in predicting potential cross-resistance to cur-
rently used regimens [14, 15].
As first-line regimens used in Chad mainly consist 
of drugs with low-genetic barriers to resistance, risks 
of HIV-1 drug resistance (HIVDR) emergence are con-
cerning. Of note, over 60% of ART failure was previ-
ously reported [14, 16], supporting the need for local 
HIVDR surveillance to sustain the effectiveness of first-
line ART, to inform on the selection of active NRTI for 
second-line combinations, to generate evidence on the 
dynamics of HIV-1 genetic diversity and potential rel-
evance on therapeutic response for patients receiving 
ART according to the current national treatment pro-
gram [5, 6].
In this study, we sought to ascertain the rate of viro-
logical failure (VF), the level of drug resistance mutations 
and HIV-1 genetic diversity among people living with 
HIV (PLHIV) receiving first-line ART as per the Chadian 
AIDS program in N’Djamena.
Methods
Study design and population
A prospective and cross-sectional study was conducted 
in PLHIV receiving first-line ART at the National Ref-
erence General Hospital of N’djamena (Hôpital Géné-
ral de Référence National de Ndjaména) in Chad, 
between 2011 and 2012. This hospital was selected as 
sentinel site based on its role as the national reference 
center in Chad, its long-term experience on ART and 
its technical capacity in providing reference laboratory 
monitoring for ARV management. Participants were 
eligible if: (a) receiving first-line ART for ≥ 6 months, 
(b) self-reported adherent to prescribed ARV medi-
cations, (c) registered and followed-up on ART at 
the study clinic, and (d) providing consent as study 
participants.
Sampling method
A non-probability sampling was used, by which patients 
were conveniently enrolled based on accessibility 
throughout the study period.
Following informed consent, participants were inter-
viewed and assessed for eligibility criteria, then enrolled 
as study participants if eligible.
Whole blood was collected in two EDTA tubes of 4 ml 
each, through venipuncture, and plasma was collected 
following centrifugation at 2000g for 10 min. Plasma ali-
quots of 1 ml were prepared and stored at − 80 °C.
Conclusions: In Chad, almost half of patients are failing first‑line antiretroviral therapy after 5 years, with considerable 
drug resistant mutations at failure. Absence of K65R supports the use of tenofovir‑containing regimens as preferred 
first‑line and as suitable drug for second‑line combinations, in this setting with significant HIV‑1 genetic diversity.
Keywords: First‑line antiretroviral therapy, Virological response, Drug resistance, HIV‑1 subtypes, Adults, Chad
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Measurement of TCD4 lymphocytes
To evaluate the stage of disease progression, CD4 T lym-
phocytes were measured for all patients at baseline and 
at 6 [± 2] months of ART, based on the fluorescent acti-
vated cell sorting approach, using the commercially avail-
able FACS Count as per the manufacturer’s instructions 
(Becton–Dickinson Immunocytometry Systems, USA).
Measurement of plasma viral load
Plasma viral load (PVL) was performed at the AIDS 
Reference Laboratory of the University Health Center 
(Laboratoire de Référence Sida du CHU) in Liege, Bel-
gium, using two different approaches purposely to ensure 
accuracy on these non-B viral populations: (1)  COBAS® 
AmpliPrep/CobasTaqman® HIV-1 version 2.0 (v2.0) 
which is based on in  vitro amplification of HIV-1 RNA 
from plasma with detection thresholds ranging from 20 
(lower) to 10,000,000 (upper) RNA copies/ml designed 
specifically for HIV-1 groups M and O; (2) the Abbott 
RealTime HIV-1 test Ref 2G3190 which is based on 
in vitro amplification by RT-PCR for the quantification of 
HIV-1 in plasma. Both PVL tests were performed as per 
manufacturers’ instructions.
VF was defined as PVL ≥ 1000 HIV-1 RNA copies/ml; 
plasma samples from study participants experiencing VF 
were designated for HIV-1 sequencing for the detection 
of DRMs and for viral subtyping.
RNA extraction, amplification and sequencing
RNA extraction
RNA extraction was performed on plasma using the 
QIAamp mini kit (Qiagen, Courtaboeuf, France), as per 
the manufacturer’s instructions. Briefly, 140  µl plasma 
samples stored at − 80  °C was extracted using lysis and 
wash buffers, followed by elution of 60 µl RNA.
Amplification and Sequencing reactions
The ANRS AC11 protocol was used for amplification 
and sequencing of the protease (PR) and reverse tran-
scriptase (RT) regions of HIV-1, using GeneAmp PCR 
System 9700 thermal cycler [17]. Briefly, amplification 
was performed using Titan One tube RT-PCR Kit ver-
sion 13 (Boehringer Mannheim, Manneheim, Germany), 
with a first-round PCR using primers amplifying 941 bp 
of RT (MJ3/MJ4) and 653 bp that encompasses the entire 
PR (5′Prot1/3′Prot1) region. Second-round (nested) 
PCR was performed with primers A35/NE(1)35 cover-
ing 731  bp of RT and primers 5′prot2/3′prot2 cover-
ing 507  bp that encompasses the entire PR. Alternative 
outer primers used for RT were RT18/RT21 and for PR 
5′eprB/3′eprB, while alternative nested primers were 
RT1/RT4 for RT and 5′prB/3′prB for PR regions. Primer 
sequences are provided in Additional file 1.
Revelation of PCR products was done using 4% eth-
idium bromide agarose gel electrophoresis, with an 
expected size of 731 pb for RT and 507 for PR, includ-
ing positive and negative controls alongside a molecu-
lar ladder (Tacklt ™ ΦX174 RF DNA/Hae III Fragment). 
Amplicons were purified PCR using  NucleoFast® 96 PCR 
(Macherey–Nagel).
As per the ANRS AC11 protocol, HIV-1 PR-RT was 
sequenced using overlapping primers by deoxytermina-
tors [17]. Sequences were purified using resin Sephadex 
G-50, and identified following capillary electrophoresis 
on a “3730” genetic analyzer of Applied Biosystem (ABI).
Interpretation of HIV‑1 drug resistance
Following the sequencing protocol used [17], HIV-1 
DRMs were interpreted according to the ANRS AC11 
algorithm (http://www.hivfrenchresistance.org/). Viruses 
with a mutant or a mixture of wild type and mutant, at an 
amino acid’s position, were considered to have the resist-
ant variant. Patients were considered as harbouring wild 
type viruses if their viral load was < 1000 RNA copies/ml 
(virological success) or with a non-amplifiable sample.
HIV‑1 phylogenetic analysis
Sequence alignment was done using CLUSTAL W ver-
sion 1.7, then sequences were trimmed and gaps closed 
[18]. Phylogenetic inference was performed with MEGA 
version 6 [19], using Neighbor Joining with 1000 repli-
cates and Kimura two-parameter [20, 21]. Subtypes were 
assigned for bootstrap ≥ 70% with a reference sequences 
from a pure HIV-1 subtype or recombinant strain 
obtained from Genbank (http://www.hiv.lanl.gov/).
Statistical analysis
Data were processed using EPI INFO version 3.3.2. Chi 
square test was used for analysing categorical data on 
VF according to ART regimens, including 95% CI, with 
a P  <  0.05 considered statistically significant. Spear-
man correlation was used for quantitative data on PVL 
results obtained from the two different instruments, with 
R ≥ 0.8 considered as a strong positive correlation.
Results
Profile of study participants
Overall, 116 PLHIV treated at the National Reference 
General Hospital of N’djamena were enrolled in the 
study, divided into 59% (68) female versus 41% (48) male. 
Mean age of these participants was 41 (±  6.87) years, 
min–max: 17–84  years (Additional file  2). Median CD4 
was 248 [interquartile range (IQR) 145; 504] cells/mm3, 
min–max: 11–684 cells/mm3.
Among study participants, the median time-on-
ART was 5 [IQR 4; 7] years. In terms of first-line drug 
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regimens commonly prescribed at the study period, 87% 
(101/116) were receiving nevirapine (NVP) plus lamivu-
dine (3TC) plus zidovudine (AZT) or stavudine (d4T), 
followed by 11% on a tenofovir-containing regimen 
(Table 1).
Viral measurements and virological response to first‑line ART
All one hundred and sixteen study participants were 
tested for PVL using both described quantitation assays 
(Cobas AmpliPrep/TaqManv2.0 and Abbott Real time 
HIV-1), and 109 samples yield comparable levels of 
HIV-1 RNA copies between both assays. A strong posi-
tive correlation  (R2  =  0.96016) was observed between 
both PVL assays (Fig.  1), with only two samples 
reported  “not detected” with Abbott Real time HIV-1 and 
detected as low-levels (2.23 and 2.68  Log10 RNA copies/
ml) viremia with Cobas AmpliPrep/TaqMan v2.0. Over-
all, both PVL assays accurately detect all patients with VF 
(≥  1000 HIV-1 RNA copies/ml). Further characteristics 
of the two assays are provided in Additional file 3.
Out of 116 participants, 50 (43%) experienced VF. 
Between the two most prescribed regimens, VF was 
higher with d4T-containing (49% [24/49]) compared to 
other regimens (39% [26/67]), odd ratio (OR): 1.514 [95% 
CI 0.672–3.417), P = 0.274 (see Table 2).
The low number of participants on the other regi-
mens could not allow a relevant statistical evaluation of 
response to ART.
HIV‑1 drug resistance mutations
Sequencing performance
All 50 samples from patients classified as VF (PVL ≥ 1000 
HIV-1 RNA copies/ml) were processed for HIV-1 geno-
typic resistance testing (GRT), resulting to 86% (43/50) 
Table 1 Prescribed antiretroviral regimens
ABC Abacavir, AZT Zidovudine, 3TC lamuvidine, EFV efavirenz, NVP nevirapine, 
d4T stavudine, TDF tenofovir, FTC emtricitabine







Fig. 1 Correlation analysis between Abbott Real time HIV‑1 and  CobasTaqman®. Log10 represents the logarithm value from absolute numbers of 
plasma viral loads
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sequencing performance with the ANRS AC11 genotyp-
ing protocol [17].
HIV‑1 mutations associated with resistance to reverse 
transcriptase inhibitors
The overall rate of patients with DRMs to reverse tran-
scriptase inhibitors was 32% (37/116), including both 
nucleoside and non-nucleoside inhibitors.
Thirty-four participants had at least one major DRM 
to nucleoside reverse transcriptase inhibitors (NRTIs), 
resulting to 29% (34/116) prevalence of NRTI DRMs in the 
entire study population. Out of the 43 sequences generated, 
the most prevalent DRMs were: (67% [29/43] M184V/I, 
30% [13/43] T215Y/F, 19% [8/43] V75A/F/I/L/M, 9% [4/43] 
K70P/R/W, 9% [4/43] K219E/N/Q and 5% [2/43] A62V, fol-
lowed by other DRMs observed at low rates (Fig. 2).
Thirty-seven participants had at least one major DRM 
to non-nucleoside reverse transcriptase inhibitors (NNR-
TIs), resulting to 32% (37/116) prevalence in the entire 
study population. Out of the 43 sequences generated, 
the most prevalent DRMs were: 30% [13/43] K103N/S/E, 
26% [11/43] Y181C/V/F/L, 2% [1/43] L100I, 2% [1/43] 
F227L and 2% [1/43] P225H, followed by other DRMs 
observed at lower rates. Of note, Y181C/F and K103N 
were observed concomitantly in three (7%) cases. Thus, 
in the entire study population, NNRTI DRMs exhibit 28% 
(32/116) and 21% (24/116) high-level resistance to nevi-
rapine and efavirenz respectively (Fig. 3).
OF note, six (12%) patients, classified as VF, were 
reported without any DRMs, suggesting possible poor 
adherence in spite of the self-reported adherence reg-
istered prior to enrolment. The list of genotypic scores 
associated to each RTI is provided in Additional file 4.
Table 2 Virological failure per antiretroviral regimens
Italic value indicates the most prescribed antiretroviral regimen
ABC Abacavir, AZT Zidovudine, 3TC lamuvidine, EFV efavirenz, NVP nevirapine, 
d4T stavudine, TDF tenofovir, FTC emtricitabine
Treatment regimens Patients per regimen Virological failure 
per regimen, n (%)
AZT+3TC+NVP 53 19 (35.85%)
d4T+3TC+NVP 48 23 (47.92%)
FTC+TDF+EFV 13 6 (46.15%)
ABC+3TC+EFV 1 1 (100%)
ABC+3TC+EFV 1 1 (100%)
Fig. 2 Prevalence of NRTI DRMs. NRTI nucleoside reverse transcriptase inhibitors, RT reverse transcriptase, DRMs drug resistant mutations
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HIV‑1 mutations associated with resistance to protease 
inhibitors
Only one patient (< 1%) was reported with major DRMs 
to protease inhibitors (PI/r), among which M46I, I54V, 
and V82S, indicating either an event of transmitted PI-
associated DRMs or unknown past-exposure to PIs. 
Minor mutations found were mainly polymorphisms: 
K20I/M (21), L10I/V (15), L90W (1), L76S (1), N88D (1), 
V11I (1), V32L (1) and G48R (1).
HIV‑1 genetic diversity
The 43 protease-RT sequences generated clustered 
within six clades (five pure subtypes and one recombi-
nant). Of note, the two equally most prevailing were sub-
type J (30%) and CRF02_AG (30%), followed by subtypes 
G (16%), A (9%), D (9%) and F (5%), as shown in Fig. 4.
Discussion
The success of combination ART has remarkably 
changed the paradigm in the AIDS epidemics globally. 
However, such achievements could rapidly be hampered 
in settings where ART is mainly based on drugs with low 
genetic barrier to resistance [14, 22, 23]. Since PLHIV in 
Chad are treated with RTI- or PI/r-containing regimens, 
evaluating the virological response, acquired HIVDR and 
circulating strains are of great programmatic asset in sus-
taining ART performance in a medium-long run [6, 15, 
16].
Our findings indicated that, about 5  years after ART 
initiation, almost half of PLHIV on first-line NRTI/
NNRTI regimens in Chad would be experiencing VF, 
suggesting close virological monitoring is needed in the 
country ART program [15, 24–27]. More importantly, as 
Fig. 3 Prevalence of NNRTI DRMs. NNRTI non‑nucleoside reverse transcriptase inhibitors, DRMs drug resistant mutations
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higher (though non-significant) rate of VF was observed 
with d4T-containing regimens (49% vs. 39% for other 
regimens, OR  =  1.514), added to the known adverse 
effects of this, our findings support effective phasing-out 
of d4T from first-line ART regimens from this setting, 
while monitoring for cross-resistance to AZT and other 
NRTIs commonly used in first- and second-line combi-
nations [6, 14, 28].
The high rate of VF in our cohort could be attributed 
to infrequent PVL measurement in 2011–2012 due to 
the centralized system, thus resulting to delayed testing 
and suboptimal monitoring. At the moment of the study, 
VL was possible only at the National Reference General 
Hospital of N’djamena, the only facility nationwide 
whereby VL is routinely offered since 2005 to date. Pres-
ently, the Entre-aide 92 team from Paris is assessing the 
feasibility of using GeneXpert for point-of-care VL in the 
cities of Moundou and Am Timan, in order to scale-up 
access to VL in Chad [29]. Therefore, although based on 
a limited sample, our findings could be representative of 
the general country situation.
Amongst those experiencing VF, relatively lower rates 
of NRTI and NNRTI mutations were found, possibly due 
to suboptimal adherence, in the frame of poor ART mon-
itoring. This calls for an improved adherence support to 
enhance and sustain viral suppression in the country [29].
Fig. 4 Phylogenetic tree. The evolutionary history was inferred using the Neighbor‑Joining method in the protease‑reverse transcriptase regions 
(Saitou and Nei [20]). The tree is drawn to scale, with branch lengths in the same units as those of the evolutionary distances used to infer the phy‑
logenetic tree. The evolutionary distances were computed using the Kimura 2‑parameter method (Kimura [21]) and are in the units of the number 
of base substitutions per site. The analysis involved 43 query nucleotide sequences. All positions containing gaps and missing data were eliminated. 
Evolutionary analyses were conducted in MEGA6 (Tamura et al. [19])
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For an accurate evaluation of virological response, a 
strong positive correlation in PVL was reported for sam-
ples tested concomitantly with two different platforms, 
which in turns confirms assay reliability in settings where 
non-B HIV-1 prevails [23]. Of note, the two discrepant 
cases were patients with low-level PVL (<  1000 copies/
ml), both clinically classified as virological success [3], or 
blips (transient rebound in PVL returning to undetect-
able levels with adherence) [8].
As levels of acquired HIVDR are higher to NNRTIs 
(32%) compared to NRTIs (29%), conferring high-level 
resistance to NVP and EFV (mainly due to K103N and 
Y181C), NRTIs are more prone for use in second-line 
combinations in such ART program [30–32]. Of note, 
K65R, the main DRM to TDF was not detected, sup-
porting TDF-containing NRTIs as preferred combina-
tions to second-line LPV/r, as globally recommended [3, 
14]. Moreover, our data also support using the combi-
nation of TDF plus (FTC or 3TC) plus EFV as the most 
prominently active first-line regimen in such RLS, at the 
moment [9, 14]. Even though 3TC and FTC are highly 
hampered by M184V (~  29%) in the overall study pop-
ulation, the ability of this mutation in decreasing viral 
replicative fitness and in improving susceptibility to thy-
midine analogs suggest maintaining these drugs (3TC 
and FTC) within current treatment guidelines [3, 9, 33, 
34]. Very low resistance to ABC also favors this drug as 
a suitable NRTI substitute for second-line combination, 
especially in case of counter indication to TDF [3, 35, 36]. 
Most importantly, the very low-level of HIVDR to PI/r 
confirms the suitability to LPV/r, ATV/r and other PI/r 
as backbone for second-line ART, in combination with 
potentially active NTRIs [3, 6, 9, 13].
A higher prevalence of CRF02_AG was found in Chad 
as compared to previous findings [10, 12], possibly due 
the ability of AG-recombinant in being more infectious 
but with less cytopathic effect [37–40]. Our small sam-
ple (43 sequences) therefore calls for enlarged molecu-
lar epidemiology studies to better understand the HIV-1 
genetic diversity, its evolution overtime and related clini-
cal relevance in the country [41].
A study limitation would be the “self-reported” adher-
ence, making it difficult to verify the reliability of recalls. 
Phasing out of D4T may suggest not representativeness 
of the data on current ART regimens. However, D4T is 
the same drug class with AZT (analogs of TAMs), and 
several patients have been exposed to these drugs. Our 
findings are therefore useful for all patients with past-
exposure to the drug class of TAMs [42, 43].
Complementary studies are needed to ascertain 
response after switch from first- to second-line [9, 44, 
45], to evaluate the feasibility of point-of-care resistance 
testing designed with commonly found mutations 
(M184V/I, T215mutants, K103N, Y181C) for greater 
cost-effectiveness [46, 47], and monitoring HIVDR early 
warning indicators [48].
Programmatic implications for the ART program in Chad
Our findings address issues that could be translated 
into policies. Of note, in addition to the need for closed 
viral load monitoring for timely detection of treatment 
failures, the high failure rate of ART in Chad also indi-
cates a rapid switch of patients from first- to second-line 
ART regimens. Rapid switch to second-line ART lead 
to increased costs of ARVs provision for the national 
HIV program in Chad, thus representing a major pro-
grammatic challenge for such RLS. Interestingly, the 
unusually low rate of DRMs, developing after signifi-
cant periods of treatment failure, suggests suboptimal 
adherence, thereby underscores the usefulness to closely 
monitor ART adherence and the need for confirming VF 
(i.e. a second viral load after counselling and adherence 
support) before deciding on ART switch. Such measure 
would help clinicians in distinguishing elevated viremia 
due to non-adherence, thereby limiting unnecessary 
switch to second-line regimens while saving related-costs 
in the national ART program of Chad.
Conclusions
About half of Chadian PLHIV experienced VF by 
medium-term after ART initiation, suggesting closed 
virological monitoring using commonly available com-
mercial assays. For successful phasing-out of d4T, DRMs 
supports using current WHO-recommended TDF plus 
TFC (or 3TC) plus EFV as preferred first-line regimen 
in Chad, while LPV/r is potentially active as second-line 
backbone, alongside “TDF” or “ABC”, in association with 
NRTIs. The predominant rate of recombinant AG is a 
quest for further investigation within the sub-region.
Additional files
Additional file 1. PCR and sequencing Primers (ANRS AC 11). The primer 
sequences are designed for amplification and sequencing reactions of 
protease and reverse transcriptase regions.
Additional file 2. Study participants by age range. The table details the 
study population by range age from 17 to over 60 years old, divided by 
male and female.
Additional file 3. Characteristics of assays used for plasma viral load. 
The table reports the minimal and maximal values, as well as mean and 
median of viral loads, obtained on one hand with Cobas and on the other 
hand with Abbott.
Additional file 4. Level of resistance to reverse transcriptase inhibitors. 
The table presents the proportion of patients with levels of genotypic 
susceptibility score following the Stanford algorithm.
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